Major VC Rounds For AI-driven Biotechs in 2020
The ongoing COVID19 crisis forced biotech-oriented venture capitalists (VC) to somewhat slow down the pace of their usual deal-flow -- according to data by PitchBook biopharma venture deals in 2020 are down roughly 16% compared to last year.
However, there is still a lot going on in drug discovery and healthcare, and here I would like to specifically focus on artificial intelligence (AI)-driven biotech and health tech startups who managed to raise notable rounds in 2020, so far (based on our report “A Landscape of Artificial Intelligence (AI) In Drug Discovery and Development”). The deals are ordered by the amount of money raised
Topics: Startups & Deals